Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

University of Minnesota Researchers Find Evidence of Genetic Link to Breast Density

June 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 6
Volume 11
Issue 6

Researchers at the University of Minnesota Cancer Center have found evidence that mamographic breast density, a measure of the relative proportions of fat, connective tissue, and glandular epithelial tissue in the breast that is a strong, independent

Researchers at the University of Minnesota Cancer Center have foundevidence that mamographic breast density, a measure of the relative proportionsof fat, connective tissue, and glandular epithelial tissue in the breastthat is a strong, independent predictor of breast cancer risk, is geneticallyinfluenced. The study, published in the April 16th Journal of the NationalCancer Institute, also suggests that 12% of the population has a geneticmutation that results in a breast density twice that of women without themutation.

"It isn't known how high breast density increases the risk of breastcancer," said lead investigator Thomas Sellers, associate professorof epidemiology and associate director of the Cancer Center. "Butthe risk is considered second only to the risk incurred by mutations inthe BRCA1 and BRCA2 genes."

The researchers obtained routine mammograms and a variety of health-relateddata from 1,370 women from 258 different Minnesota families. The studypopulation included 65 mother-daughter pairs and 275 sister-sister pairs.All of the women were related, either genetically or by marriage, to anoriginal group of 544 breast cancer patients seen at the University ofMinnesota between 1944 and 1952. Sellers and colleagues are studying thesefamilies as part of the Breast Cancer Family Cohort study.

Breast Density Partly Modifiable

Sellers says that the study is significant because the researchers wereable to separate out other risk factors, such as waist-to-hip ratio, physicalactivity, hormone replacement therapy, and number of live births, to detecta Mendelian dominant inheritance pattern (a pattern where only one copyof the mutated gene is necessary to transfer the trait to offspring). Theywere unable, however, to completely eliminate the possibility of a recessivepattern, which would require more than one copy of a gene to produce atrait. However, if breast density is, indeed, controlled by a dominantgene, about 12% of the population would be expected to carry a form ofthe gene that results in a breast density about twice that of the restof the population. "The good news is that while breast density riskfactor is partly genetic, it's also shaped by the environment, and so canbe modified," Sellers said.

In previous studies, Sellers and colleagues have reported on potentialrisk factors for breast cancer, including waist-to-hip ratio, fat in thediet, and the connection between breast cancer in women and prostate cancerin men. These finding stem from the Iowa Women's Study, an ongoing healthstudy of more than 40,000 women in Iowa.

Articles in this issue

Use of Adjuvent Analgesics Profiled at Pain Conference
Chromosomal Changes Linked to Family History of Lung Cancer
Bacterial Infection in Patients With Cancer: Focus on Prevention
Docetaxel in Combined Modality Therapy for Breast Cancer
Role of Diet in Cancer Hard to Study, Expert Says
Anti-HIV Effects of Viracept Persist During Long Periods of Combination Therapy
University of Minnesota Researchers Find Evidence of Genetic Link to Breast Density
Guidelines for the Early Referral of Patients to Cancer Specialists
New Drugs May Brighten Ovarian Cancer Picture
Researchers Hope Function of BRCA1 Gene Holds Key to New Treatments
Research Points to Effectiveness of Brachytherapy in Early Prostate
Lung Cancer Surgical Practice Guidelines
Pituitary Adenomas: Current Methods of Diagnosis and Treatment
Management of Carcinoma of the Superior Pulmonary Sulcus
SSO Practice Guidelines: Introductory Remarks

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Related Content

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

Teclistamab is Feasible for Select Elderly Patients with Multiple Myeloma

Roman Fabbricatore
May 16th 2025
Article

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Mary Katherine L. Anderson, MD;James P. Fagerland, MD;Samantha Kohn, MD, MS;Amy C. Cannella, MD;Benjamin A. Teply, MD
May 16th 2025
Article

This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


"[The Teal Wand] offers an evidence-based way to expand access [to screening] without compromising accuracy,” according to Christine Conageski, MD, MSc, from the University of Colorado Anschutz Medical Campus.

FDA Approves At-Home Cervical Cancer Screening Kit

Ariana Pelosci
May 15th 2025
Article

Teal Wand showed a 95% positive percent agreement when screening for cervical cancer.


61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Camila Ortega;Micah Brainerd;Christopher Mamone;Caroline Mangira;Andrew Fenton;Mary Murray
May 15th 2025
Article
Related Content

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

Teclistamab is Feasible for Select Elderly Patients with Multiple Myeloma

Roman Fabbricatore
May 16th 2025
Article

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Mary Katherine L. Anderson, MD;James P. Fagerland, MD;Samantha Kohn, MD, MS;Amy C. Cannella, MD;Benjamin A. Teply, MD
May 16th 2025
Article

This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


"[The Teal Wand] offers an evidence-based way to expand access [to screening] without compromising accuracy,” according to Christine Conageski, MD, MSc, from the University of Colorado Anschutz Medical Campus.

FDA Approves At-Home Cervical Cancer Screening Kit

Ariana Pelosci
May 15th 2025
Article

Teal Wand showed a 95% positive percent agreement when screening for cervical cancer.


61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Camila Ortega;Micah Brainerd;Christopher Mamone;Caroline Mangira;Andrew Fenton;Mary Murray
May 15th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.